Cyr61 是前列腺癌的一个潜在预后标志物。
Cyr61 is a potential prognostic marker for prostate cancer.
机构信息
Department of Urology, the James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
出版信息
Asian J Androl. 2012 May;14(3):405-8. doi: 10.1038/aja.2011.149. Epub 2012 Feb 20.
Abstract
Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling that is frequently altered in expression in several types of cancers. In prostate cancer (PCa), Cyr61 is highly expressed in organ-confined disease. Further, Cyr61 expression levels are associated with a lower risk of disease recurrence, and can be quantitatively measured in the serum. Considered together, these results indicate that Cyr61 is a potential and clinically useful tissue, as well as serum-based biomarker for differentiating lethal and non-lethal PCa.
摘要
富含半胱氨酸的血管生成诱导因子 61（Cyr61）是一种细胞外基质蛋白，参与生长因子和激素信号的转导，在多种类型的癌症中表达经常改变。在前列腺癌（PCa）中，Cyr61 在器官受限疾病中高度表达。此外，Cyr61 的表达水平与疾病复发的风险较低相关，并且可以在血清中定量测量。综合这些结果表明，Cyr61 是一种潜在的、临床上有用的组织，也是血清为基础的生物标志物，用于区分致命性和非致命性前列腺癌。
相似文献
1
Cyr61 is a potential prognostic marker for prostate cancer.
Asian J Androl. 2012 May;14(3):405-8. doi: 10.1038/aja.2011.149. Epub 2012 Feb 20.
2
Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment.
Clin Cancer Res. 2010 Dec 1;16(23):5908-13. doi: 10.1158/1078-0432.CCR-10-1200.
3
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.
Prostate. 2012 Jun 15;72(9):966-76. doi: 10.1002/pros.21501. Epub 2011 Oct 24.
4
Cyr61: a potential therapeutic target for prostate cancer.
Asian J Androl. 2014 Sep-Oct;16(5):788-9. doi: 10.4103/1008-682X.128517.
5
Expression of Cyr61 in primary salivary adenoid cystic carcinoma and its relation to Ki-67 and prognosis.
Oral Oncol. 2011 May;47(5):365-70. doi: 10.1016/j.oraloncology.2011.02.022. Epub 2011 Mar 24.
6
CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
BMC Cancer. 2019 Nov 25;19(1):1140. doi: 10.1186/s12885-019-6321-x.
7
Cysteine-rich, angiogenic inducer, 61 expression in patients with ovarian epithelial carcinoma.
J Int Med Res. 2014 Apr;42(2):300-6. doi: 10.1177/0300060513505268. Epub 2014 Mar 4.
8
Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer.
PLoS One. 2007 Jun 20;2(6):e534. doi: 10.1371/journal.pone.0000534.
9
CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma.
Oncotarget. 2016 May 24;7(21):31067-78. doi: 10.18632/oncotarget.8845.
10
Extracellular matrix associated protein CYR61 is linked to prostate cancer development.
J Urol. 2010 Apr;183(4):1604-10. doi: 10.1016/j.juro.2009.12.006. Epub 2010 Feb 20.
引用本文的文献
1
CYR61 as a Potential Biomarker and Target in Cancer Prognosis and Therapies.
Cells. 2025 May 22;14(11):761. doi: 10.3390/cells14110761.
2
Chemotherapy-initiated cysteine-rich protein 61 decreases acute B-lymphoblastic leukemia chemosensitivity.
J Cancer Res Clin Oncol. 2024 Mar 26;150(3):159. doi: 10.1007/s00432-024-05692-8.
3
Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
BMC Genomics. 2024 Feb 16;25(1):183. doi: 10.1186/s12864-024-10056-0.
4
The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery.
Biomedicines. 2023 Dec 28;12(1):79. doi: 10.3390/biomedicines12010079.
5
Cross-sectional and longitudinal associations of serum Cysteine-rich 61 with severity and prognosis among community-acquired pneumonia patients in China.
Front Med (Lausanne). 2022 Aug 11;9:939002. doi: 10.3389/fmed.2022.939002. eCollection 2022.
6
Evaluation of Schott in anti-cancerous properties with proximity extension assays.
Food Nutr Res. 2021 Oct 4;65. doi: 10.29219/fnr.v65.7549. eCollection 2021.
7
Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.
Biosci Rep. 2021 Jun 25;41(6). doi: 10.1042/BSR20204117.
8
Urinary Cysteine-Rich Protein 61 and Trefoil Factor 3 as Diagnostic Biomarkers for Colorectal Cancer.
Transl Oncol. 2019 Mar;12(3):539-544. doi: 10.1016/j.tranon.2018.12.006. Epub 2019 Jan 3.
9
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.
Ther Adv Med Oncol. 2017 Aug;9(8):565-573. doi: 10.1177/1758834017719215. Epub 2017 Jul 5.
10
Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.
Clin Transl Oncol. 2017 Apr;19(4):519-524. doi: 10.1007/s12094-016-1560-7. Epub 2016 Oct 14.
本文引用的文献
1
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.
Prostate. 2012 Jun 15;72(9):966-76. doi: 10.1002/pros.21501. Epub 2011 Oct 24.
2
Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment.
Clin Cancer Res. 2010 Dec 1;16(23):5908-13. doi: 10.1158/1078-0432.CCR-10-1200.
3
Extracellular matrix associated protein CYR61 is linked to prostate cancer development.
J Urol. 2010 Apr;183(4):1604-10. doi: 10.1016/j.juro.2009.12.006. Epub 2010 Feb 20.
4
Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis.
Mol Cancer Res. 2009 Jul;7(7):1045-55. doi: 10.1158/1541-7786.MCR-09-0017. Epub 2009 Jul 7.
5
Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells.
Br J Cancer. 2008 Nov 18;99(10):1656-67. doi: 10.1038/sj.bjc.6604712. Epub 2008 Oct 21.
6
Functions and mechanisms of action of CCN matricellular proteins.
Int J Biochem Cell Biol. 2009 Apr;41(4):771-83. doi: 10.1016/j.biocel.2008.07.025. Epub 2008 Aug 15.
7
Prostate cancer: genes, environment, immunity and the use of immunotherapy.
Prostate Cancer Prostatic Dis. 2008;11(3):230-6. doi: 10.1038/pcan.2008.3. Epub 2008 Feb 19.
8
Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients.
Urology. 2007 Oct;70(4):743-7. doi: 10.1016/j.urology.2007.06.1102.
9
Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response.
Int J Biochem Cell Biol. 2008;40(1):98-109. doi: 10.1016/j.biocel.2007.06.020. Epub 2007 Jul 26.
10
Diagnosis of adenocarcinoma in prostate needle biopsy tissue.
J Clin Pathol. 2007 Jan;60(1):35-42. doi: 10.1136/jcp.2005.036442.
Zotero 插件